文献速递淋巴瘤造血干细胞移植与细胞治疗

大B细胞淋巴瘤患者在接受CAR-T细胞治疗前后使用他法西他单抗联合来那度胺的结局

Outcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapy.
PubMed 文献 · Blood Adv · 2024-01-01

研究基于DESCAR-T注册库分析大B细胞淋巴瘤患者,在CAR-T(axi-cel或tisa-cel)治疗前(n=15)或后(n=52)接受他法西他单抗联合来那度胺(TAFA-LEN)的结局。CAR-T后使用TAFA-LEN者中位无进展生存2为3个月、中位总生存2为4.7个月,最佳总缓解率13.5%、最佳完全缓解率7.7%;与其它治疗相比结局相似。CAR-T后复发>6个月者结局更好。

要点

  • CAR-T后使用TAFA-LEN的中位PFS2为3个月、OS2为4.7个月、DOR2为8.1个月。
  • CAR-T后使用TAFA-LEN的最佳总缓解率13.5%、最佳完全缓解率7.7%。
  • CAR-T后复发>6个月者PFS2为5.6 vs 2个月(P=.0138),OS2未达到 vs 3.8个月(P=.0034)。

核心结论

  • 无论是TAFA-LEN还是比较性挽救治疗,均未改善CAR-T细胞治疗后复发患者的结局。

研究设计与样本

  • 基于DESCAR-T注册库的分析,纳入≥3线接受axi-cel或tisa-cel治疗的大B细胞淋巴瘤患者。
  • TAFA-LEN在CAR-T前使用组(TL-pre-CAR-T)n=15,在CAR-T后直接使用组(TL-post-CAR-T)n=52。
  • 在TL-post-CAR-T组中采用逆概率加权比较TAFA-LEN与其他治疗。

主要发现

  • TL-post-CAR-T组自首次进展治疗起的中位PFS2、OS2、DOR2分别为3、4.7、8.1个月。
  • TAFA-LEN后的最佳总缓解率为13.5%,最佳完全缓解率为7.7%。
  • CAR-T后>6个月复发者mPFS2为5.6 vs 2个月(P=.0138),mOS2为未达到 vs 3.8个月(P=.0034)。
  • TAFA-LEN与其他治疗的bORR为20.6% vs 24.9%,bCRR为11.6% vs 15.6%。
  • TAFA-LEN与其他治疗的mPFS2为2.9 vs 2.4个月(P=.91),mOS2为3.3 vs 5.5个月(P=.06)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tafasitamab plus lenalidomide (TAFA-LEN) treatment relevance pre- or post-anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is debated. We analyzed patients with large B-cell lymphoma in the DESCAR-T registry treated with axi[1]cel or tisa-cel in ≥3rd line and TAFA-LEN before (n = 15, "TL-pre-CAR-T" set) or directly after (n = 52, "TL-post-CAR-T" set) CAR T-cell therapy. We compared TAFA-LEN v. other treatments using inverse probability weighting in the TL-post-CAR[1]T set. In the TL-post-CAR-T set, the median progression-free survival (mPFS), overall survival (mOS), and duration of response (mDOR) since the first treatment for progression (mPFS2/mOS2/mDOR2) were 3, 4.7, and 8.1 months, respectively. The best overall response rate (bORR) and best complete response rate (bCRR) after TAFA-LEN were 13.5% and 7.7%, respectively. Outcomes were better for patients who relapsed >6 months after CAR T-cell therapy (mPFS2: 5.6 vs 2 months, P = .0138; mOS2: not reached vs 3.8 months, P = .0034). The bORR and bCRR between TAFA-LEN and other treatments were 20.6% vs 24.9% and 11.6% vs 15.6%, respectively. Outcomes were similar between TAFA-LEN and other treatments (mPFS2: 2.9 vs 2.4 months, P = .91; mOS2: 3.3 vs 5.5 months, P = .06). In an exploratory analysis of the TL-pre-CAR-T set, the median TAFA-LEN treatment duration before CAR-T was 3.7 months with no patient becoming CD19 negative. The bORR, bCRR, 6- month PFS, and OS rates after CAR T-cell infusion were 45.5%, 36.4%, 20.1%, and 58.2%, respectively. Neither TAFA-LEN nor comparative salvage treatment improved outcomes for patients relapsing after CAR T-cell therapy.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Camus V, Houot R, Brisou G, et al. Outcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapy. Blood Adv. 2024. PMID: 39163620. doi:10.1182/bloodadvances.2024013726

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。